RxDoctor Payments Data

Emily Weed, APRN

Family · Clearwater, FLNPI 1578315644

Payments from drug & device makers

$1,403in general payments, 2019–2025

Across 57 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$587
  • Madrigal Pharmaceuticals$385
  • Johnson & Johnson$180
  • Celltrion USA Inc.$97
  • Lilly USA, LLC$33
  • Aimmune Therapeutics, Inc.$31
  • plus $91 from 4 others

What the payments were for

  • Food & beverage$1,403100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,403 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$22,959
Medicare patients
181
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase30$104,004
LinzessLinaclotide38$33,673
ClenpiqSod Picosulf/Mag Ox/Citric Ac87$15,085
Mesalamine14$6,842
Mesalamine ErMesalamine12$3,902
Budesonide DrBudesonide18$3,195
Omeprazole179$2,860
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,640
Sucralfate84$2,513
Famotidine121$1,863
Pantoprazole Sodium128$1,832
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C11$1,777
Dicyclomine Hcl63$1,752
Ursodiol12$506
Metronidazole11$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$587$137,67768 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$20$1,77711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.

Other family in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →